Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Netweb Technologies shares surge 13% to record high, rally 170% in 6 months ! Here’s why
1er/10/2025
Anand Rathi Share and Stock Brokers shares rally 13% from IPO price in 2 days as investor demand stays strong
1er/10/2025
Sunny Agrawal flags overpriced unlisted stocks amid IPO frenzy
1er/10/2025
Mass layoff, major service disruption feared as US government shuts down
1er/10/2025
How this flexicap mutual fund turned Rs 1 lakh to Rs 34 lakh in 22 years
1er/10/2025
Gold hovers near record high on US shutdown concerns, Fed rate outlook
1er/10/2025
